PressSeptember 16, 2021 COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs
PressSeptember 16, 2021 Awakn Life Sciences to Acquire Leading Ketamine-assisted Psychotherapy Clinic in Norway
PressSeptember 15, 2021 Nova Mentis Life Science Applies to US FDA for Psilocybin Orphan Drug Designation Fragile X Syndrome Treatment
PressSeptember 15, 2021 Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression
PressSeptember 14, 2021 Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine
PressSeptember 13, 2021 PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022
PressSeptember 9, 2021 Field Trip Health Ltd. to Pursue Treatment Resistant Depression and Postpartum Depression as Indications for FT-104
PressSeptember 8, 2021 Journey Colab secures $12M Series A funding for Phase 1 trial of Mescaline HCl, JOUR-001, for treatment of Alcohol Use Disorder
PressSeptember 7, 2021 Field Trip Health opens Europe’s first psychedelic therapy healthcare facility
PressSeptember 3, 2021 Filament Health Files 20th Patent Application Including Three International Pct Applications
PressSeptember 3, 2021 Field Trip Health Ltd. Announces Launch Of “Kap Co-Operative” Program, Enabling Independent Psychedelic Therapists To Practice At Its Field Trip Health Centers
PressSeptember 2, 2021 MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a System for Identifying Agitation Episodes
PressSeptember 1, 2021 Red Light Holland Successfully Completes Canada’s Largest Legal Sale and Import of Psilocybe Truffles into Canada Under a Health Canada Approved Psilocybin Import Permit
PressAugust 26, 2021 Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling Addiction Led by Professor Celia Morgan
PressAugust 26, 2021 PharmaDrug Announces Clinical Research Collaboration with The Johns Hopkins University to Evaluate DMT in a Comparative Clinical Study
PressAugust 25, 2021 Tryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of Florida
